Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50% / MedCity

Frank Vinluan / medcitynews - Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for pre…

#healthcare #publichealth #biotech #medicaldevices #oncology

Achyut Saroj: Exciting News in Multicancer Detection and Liquid Biopsy

22 days / oncodaily

Ulrika Årehed Kågström: A Simple Blood Test Can Show If Cancer is On Its Way Back

22 days / oncodaily

Amol Akhade: Stage Shifts, Screening, and What Matters Most

23 days / oncodaily

Steps Toward Prevention and Early Diagnosis – Childhood Cancer International – Europe

23 days / oncodaily

How Early Detection and Intervention are Reshaping Cancer Prevention – NFCR

23 days / oncodaily

Vineet Datta: Galleri Blood Test Failed Primary Endpoint in NHS Study

23 days / oncodaily

Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50%

24 days / medcitynews / Frank Vinluan

Grail's cancer test faces new uncertainty after UK study

24 days / endpoints / Jared Whitlock

Grail's cancer test misses primary study goal in UK study

24 days / endpoints / Jared Whitlock

Saturday, February 21, 2026, 12:23 am / permalink 19500 / 9 stories in 23 days

'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice / LiveScience

livescience - In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, scientists report.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety

'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice

24 days / livescience

Closing in on a universal vaccine: Nasal spray protects mice from respiratory viruses, bacteria and allergens

25 days / medicalxpress

Single vaccine could protect against all coughs, colds and flus, researchers say

25 days / bbc

Friday, February 20, 2026, 5:22 pm / permalink 19489 / 3 stories in 24 days

Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment / Discover

discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology

Cats may hold clues for human cancer treatment

25 days / bbc

Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment

25 days / discovermagazine

Household cat could hold the key to understanding breast cancer

25 days / medicalxpress

Thursday, February 19, 2026, 9:23 pm / permalink 19449 / 3 stories in 24 days

Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV / Medical Express

medicalxpress - Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #infanthealth

Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV

25 days / medicalxpress

Paediatricians’ blood used to make new treatments for RSV and colds

26 days / newscientist

Antibody cocktails based on the occupationally acquired immunity of pediatricians neutralize and confer protection against RSV and hMPV

26 days / science / Hui Zhai, Wenxiang Yu, Jinyue Wang, Jie Deng, Siyu Lei, Teng Zhou, Yixin Li, Kaijun Xu, Mengyang Ma,

Thursday, February 19, 2026, 12:24 pm / permalink 19427 / 3 stories in 25 days

FDA formalizes one pivotal trial policy via NEJM perspective / Endpoints

Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

FDA formalizes one pivotal trial policy via NEJM perspective

25 days / endpoints / Zachary Brennan

FDA to drop 2-study requirement, expand OTC access

25 days / beckershospitalreview / Ella Jeffries

FDA will drop two-study requirement for new drug approvals, aiming to speed access

25 days / medicalxpress

Thursday, February 19, 2026, 11:24 am / permalink 19422 / 3 stories in 25 days

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine / NYT

Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #vaccinesafety

Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more

23 days / endpoints / Max Gelman

FDA's abrupt flip-flop on Moderna's mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

25 days / medicalxpress

What the Health? From KFF Health News: Turnarounds and Shake-Ups

25 days / kffhealthnews

Study shows low vaccination rates among expectant mothers in Norway against COVID-19, influenza

25 days / medicalxpress

FDA reverses course; agrees to review Moderna flu vaccine

26 days / beckershospitalreview / Erica Cerutti

Reversal on Moderna's flu application follows atypical path through FDA

26 days / endpoints / Zachary Brennan

Moderna says the FDA will consider its new flu shot after resolving a public dispute

26 days / abcnews

In reversal, US agrees to review new Moderna flu shot

26 days / medicalxpress

FDA reverses course on Moderna’s flu vaccine

26 days / healthcaredive / Delilah Alvarado

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

26 days / nytimes / Christina Jewett and Rebecca Robbins

FDA reverses course, will review Moderna’s flu vaccine

26 days / endpoints / Max Bayer

Wednesday, February 18, 2026, 9:23 am / permalink 19353 / 11 stories in 26 days

Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test / MedCity

Frank Vinluan / medcitynews - In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by R…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test

27 days / medcitynews / Frank Vinluan

Ocular Therapeutix’s Axpaxli could become first choice in wet AMD after showing superiority over Eylea

27 days / endpoints / Elizabeth Cairns

Bruce Haffty Joins ACR as the Chief Medical Officer for Radiation Oncology Research

29 days / oncodaily

Tuesday, February 17, 2026, 9:22 pm / permalink 19334 / 3 stories in 26 days

Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents / Nature

Abraham Shaked / nature - Nature Medicine, Published online: 09 February 2026; doi:10.1038/s41591-025-04196-3In a study of four brain-dead human decedents, extracorporeal liver cross-circulation using genetically modified pig livers provides essential hepatic functions, supporting…

#healthcare #publichealth #governmentpolicy #biotech #fda #medicaldevices

Vascularized liver tissueoid-on-a-chip models regeneration and transplant rejection

26 days / medicalxpress

Extracorporeal cross-circulation with genetically modified pig livers in a human decedent model

4 wks / nature

A new window into hemodialysis: How optical sensors could make treatment safer

5 wks / medicalxpress

Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents

5 wks / nature / Abraham Shaked

Saturday, February 14, 2026, 10:21 am / permalink 19188 / 4 stories in 4 wks

New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer / Discover

discovermagazine - Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

#healthcare #publichealth #biotech #fda #digitalhealth #medicaldevices #oncology #pancreaticcancer

Optune Pax Secures FDA Approval in Locally Advanced Pancreatic Cancer, Lifting NVCR 19%

26 days / oncodaily

FDA approves noninvasive Optune Pax device for advanced pancreatic cancer

26 days / medicalxpress

Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer

27 days / medicalxpress

NAPOLI 3 Subgroup Analysis: NALIRIFOX in Older Patients With Metastatic Pancreatic Cancer

27 days / oncodaily

Sensing local fibers in pancreatic tumors, cancer cells 'choose' to either grow or tolerate treatment

28 days / medicalxpress

Nina Niu Sanford Shares Update on NRG-GI011 Pancreas Cancer Trial